Brian A. Van Tine, Ph.D.

2003 University of Alabama, Birmingham, Birmingham, AL, United States 
"Brian Van Tine"
Mean distance: 9.24


Sign in to add mentor
Louise T. Chow grad student 2003 UAB
 (Segregation or integration: Images of dynamic changes from Birmingham, Alabama.)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Ohman KA, Hashim YM, Vangveravong S, et al. (2016) Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. Oncotarget
Lange SE, Zheleznyak A, Studer M, et al. (2016) Development of 89Zr-Ontuxizumab for in vivo TEM-1/endosialin PET applications. Oncotarget
Lange SE, Liu J, Adkins DR, et al. (2015) Improved Clinical Trial Enrollments for Uterine Leiomyosarcoma Patients After Gynecologic Oncology Partnership with a Sarcoma Center. Gynecologic Oncology
Demetri GD, von Mehren M, Jones RL, et al. (2015) Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Movva S, Wen W, Chen W, et al. (2015) Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets. Oncotarget. 6: 12234-47
D' Angelo SP, Mahoney MR, Van Tine BA, et al. (2015) Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma. Cancer Chemotherapy and Pharmacology. 75: 629-38
Dong Y, Van Tine BA, Oyama T, et al. (2014) Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. Cell Research. 24: 1354-66
Van Tine BA. (2014) Using molecular profiling diagnostics to identify predictive biomarkers in metastatic cancer. Mlo: Medical Laboratory Observer. 46: 18, 20-1
Zhang K, Jones L, Lim S, et al. (2014) Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget. 5: 9281-94
Chawla SP, Cranmer LD, Van Tine BA, et al. (2014) Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3299-306
See more...